Type of Study |
Study Description |
Status |
The ICARA Study |
The ICARA study is evaluating bapineuzumab, an amyloid antibody therapy aimed at slowing the progression of Alzheimer disease. Individuals with a diagnosis of probable mild to moderate Alzheimer disease are eligible to participate. |
Currently enrolling |
The Expedition Study |
The Expedition study is evaluating solaneuzumab, an amyloid antibody therapy aimed at slowing the progression of Alzheimer disease. Individuals with a diagnosis of probable mild to moderate Alzheimer disease are eligible to participate. |
Currently enrolling |
FDG-PET Imaging for Alzheimer disease |
FDG PET, the most widely available PET tracer, provides measures of regional brain glucose metabolism. FDG PET scans may help distinguish demented from normal individuals and may differentiate Alzheimer disease from other forms of dementia. This study is designed to develop more objective analyses of FDG PET imaging. |
Currently enrolling |
Alzheimer Disease Imaging Studies |
Brain imaging methods using PET (positron emission tomography) or SPECT (single photon emission computed tomography) are being developed at IND as objective and sensitive biomarkers of β-amyloid in the brain. These imaging studies are combined with memory and thinking tests. Eligible subjects have a diagnosis of probable Alzheimer disease. |
Currently enrolling |
Alzheimer Disease Non-Amyloid Imaging Studies |
Several neurochemical changes besides an accumulation of amyloid occur in the brain in individuals with Alzheimer disease. Researchers at IND are developing multiple imaging ligands to better understand the changes occurring in the brain in Alzheimer disease. Imaging ligands to detect changes in the norepinepherine system and neuroinflammation are critical to the development of future medications. |
Currently enrolling |
